Allan Saul

Allan has worked on Infectious diseases since 1979. Before retiring in January 2020 and returning to Australia, he was the Institute Director of the GSK Vaccines Institute for Global Health since its inception in 2007 working on vaccines for Typhi, Paratyphi A, Shigella, invasive nontyphoidal Salmonella and Group A streptococcus.

Prior to this position he had more than 25 years’ experience working on the development of experimental malaria vaccines, field work in epidemiology and testing control programs for malaria in endemic countries including malaria elimination programs in China and The Philippines. He also led laboratory-based research in malaria antigen identification. Allan held previous appointments at the National Institutes of Health (NIH), USA, where he was the co-branch chief of the Malaria Vaccine Development Branch and at the Queensland Institute of Medical Research in Brisbane, Australia.

His current interest is in finding practical ways to efficiently get therapeutics and diagnostics for major global health problems from initial proof of concept in humans, through Phase 3 and registration to sustainable production and implementation.